|
|
Volumn 33, Issue 7-8, 2001, Pages 3199-3200
|
|
CSA/MMF/steroids versus CSA/AZA/steroids with and without basiliximab in cadaveric kidney transplantation
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
AZATHIOPRINE;
CYCLOSPORIN A;
INTERLEUKIN 2 RECEPTOR;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
METHYLPREDNISOLONE;
MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;
THYMOCYTE ANTIBODY;
ADULT;
ARTICLE;
CADAVER KIDNEY;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DISEASE SEVERITY;
DRUG BLOOD LEVEL;
DRUG EFFICACY;
DRUG RECEPTOR BINDING;
DRUG SAFETY;
DRUG TOLERANCE;
ECONOMIC EVALUATION;
FEMALE;
GRAFT SURVIVAL;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
INFECTION RATE;
KIDNEY GRAFT REJECTION;
KIDNEY TRANSPLANTATION;
LYMPHOCYTE ACTIVATION;
MAJOR CLINICAL STUDY;
MALE;
MULTICENTER STUDY;
POSTOPERATIVE INFECTION;
PRIORITY JOURNAL;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADULT;
ANTIBODIES, MONOCLONAL;
AZATHIOPRINE;
CADAVER;
CYCLOSPORINE;
DRUG THERAPY, COMBINATION;
FEMALE;
HISTOCOMPATIBILITY TESTING;
HUMANS;
KIDNEY TRANSPLANTATION;
MALE;
MIDDLE AGED;
MYCOPHENOLIC ACID;
RECOMBINANT FUSION PROTEINS;
RETROSPECTIVE STUDIES;
STEROIDS;
TISSUE DONORS;
|
|
EID: 0035679181
PISSN: 00411345
EISSN: None
Source Type: Journal
DOI: 10.1016/S0041-1345(01)02361-2 Document Type: Article |
|
Times cited : (4)
|
|
References (10)
|
